BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 21518926)

  • 1. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
    Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ
    Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
    Yamagata K; Shino M; Aikawa Y; Fujita S; Kitabayashi I
    Leukemia; 2021 Oct; 35(10):2840-2853. PubMed ID: 33967269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
    Nguyen AT; Taranova O; He J; Zhang Y
    Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
    Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
    J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
    Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
    Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
    J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.
    Milne TA; Martin ME; Brock HW; Slany RK; Hess JL
    Cancer Res; 2005 Dec; 65(24):11367-74. PubMed ID: 16357144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
    Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.
    Skucha A; Ebner J; Schmöllerl J; Roth M; Eder T; César-Razquin A; Stukalov A; Vittori S; Muhar M; Lu B; Aichinger M; Jude J; Müller AC; Győrffy B; Vakoc CR; Valent P; Bennett KL; Zuber J; Superti-Furga G; Grebien F
    Nat Commun; 2018 May; 9(1):1983. PubMed ID: 29777171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
    Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
    J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning from mouse models of MLL fusion gene-driven acute leukemia.
    Schwaller J
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
    Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
    Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
    Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
    Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.
    Thiel AT; Blessington P; Zou T; Feather D; Wu X; Yan J; Zhang H; Liu Z; Ernst P; Koretzky GA; Hua X
    Cancer Cell; 2010 Feb; 17(2):148-59. PubMed ID: 20159607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disordered epigenetic regulation in MLL-related leukemia.
    Zhang Y; Chen A; Yan XM; Huang G
    Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
    Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
    Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
    Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
    PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When epigenetics kills: MLL fusion proteins in leukemia.
    Slany RK
    Hematol Oncol; 2005 Mar; 23(1):1-9. PubMed ID: 16118769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of MLL-associated leukemia.
    Yokoyama A
    Int J Hematol; 2015 Apr; 101(4):352-61. PubMed ID: 25773519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.